These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 17186008)

  • 1. Cardiac repolarization and the safety of new drugs defined by electrocardiography.
    Morganroth J
    Clin Pharmacol Ther; 2007 Jan; 81(1):108-13. PubMed ID: 17186008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lessons learned from independent central review.
    Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
    Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contraceptive development and clinical trials.
    Fraser IS
    Clin Reprod Fertil; 1986 Feb; 4(1):75-85. PubMed ID: 3708511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evidence used for approval of new drugs.
    Botstein P
    Isr J Med Sci; 1986; 22(3-4):197-200. PubMed ID: 3528042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Importance and challenges of studying marketed drugs: what is a phase IV study? Common clinical research designs, registries, and self-reporting systems.
    Glasser SP; Salas M; Delzell E
    J Clin Pharmacol; 2007 Sep; 47(9):1074-86. PubMed ID: 17766697
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Critical assessment of international clinical development programmes for new antihypertensive drugs.
    Ménard J
    J Hypertens Suppl; 1993 Dec; 11(5):S39-46. PubMed ID: 8158432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Approaches to the development and marketing approval of drugs that prevent cancer.
    Kelloff GJ; Johnson JR; Crowell JA; Boone CW; DeGeorge JJ; Steele VE; Mehta MU; Temeck JW; Schmidt WJ; Burke G
    Cancer Epidemiol Biomarkers Prev; 1995; 4(1):1-10. PubMed ID: 7894318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. From translational research to a large randomized clinical trial: a long and streanuous way from bench to bedside.
    Sakamoto J; Morita S
    Nagoya J Med Sci; 2007 Jan; 69(1-2):9-16. PubMed ID: 17378175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Investigational drug tracking: phases I-III and NDA submissions--Part II.
    Grant KL
    Hosp Pharm; 1994 Oct; 29(10):900, 902-4, 906-11 passim. PubMed ID: 10137850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Drug evaluation in neuroanesthesia and resuscitation].
    Autret E
    Agressologie; 1991; 32(6-7):307-9. PubMed ID: 1843832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecularly targeted oncology therapeutics and prolongation of the QT interval.
    Strevel EL; Ing DJ; Siu LL
    J Clin Oncol; 2007 Aug; 25(22):3362-71. PubMed ID: 17664484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular safety of drugs not intended for cardiovascular use: need for a new conceptual basis for assessment and approval.
    Borer JS; Pouleur H; Abadie E; Follath F; Wittes J; Pfeffer MA; Pitt B; Zannad F
    Eur Heart J; 2007 Aug; 28(15):1904-9. PubMed ID: 17615083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New drug and biological drug products; evidence needed to demonstrate effectiveness of new drugs when human efficacy studies are not ethical or feasible. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2002 May; 67(105):37988-98. PubMed ID: 12049094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human carcinogenic risk evaluation, Part III: Assessing cancer hazard and risk in human drug development.
    Jacobs A; Jacobson-Kram D
    Toxicol Sci; 2004 Oct; 81(2):260-2. PubMed ID: 15141097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The FDA's generic-drug approval process: similarities to and differences from brand-name drugs.
    Kefalas CH; Ciociola AA
    Am J Gastroenterol; 2011 Jun; 106(6):1018-21. PubMed ID: 21637264
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical trials bureaucracy: unintended consequences of well-intentioned policy.
    Califf RM
    Clin Trials; 2006; 3(6):496-502. PubMed ID: 17170032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Air pollution effects on ventricular repolarization.
    Lux RL; Pope CA
    Res Rep Health Eff Inst; 2009 May; (141):3-20; discussion 21-8. PubMed ID: 19579527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How do pharmaceutical companies approach data from sexual health studies for regulatory agencies?
    Dilleen M; Haughie S
    Annu Rev Sex Res; 2005; 16():53-61. PubMed ID: 16913287
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Institute of Medicine's new drug safety report: implications for Canada.
    Cassels A
    CMAJ; 2006 Dec; 175(12):1515-6. PubMed ID: 17146086
    [No Abstract]   [Full Text] [Related]  

  • 20. Current challenges in the evaluation of cardiac safety during drug development: translational medicine meets the Critical Path Initiative.
    Piccini JP; Whellan DJ; Berridge BR; Finkle JK; Pettit SD; Stockbridge N; Valentin JP; Vargas HM; Krucoff MW;
    Am Heart J; 2009 Sep; 158(3):317-26. PubMed ID: 19699852
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.